创伤后应激障碍的代谢重编程：用于精准治疗的GLP-1受体激动剂和心脏代谢药物再利用

Post-traumatic stress disorder (PTSD) is increasingly recognized as a systemic disorder closely linked to metabolic dysfunction, including obesity, insulin resistance, type 2 diabetes and cardiovascular disease. These comorbidities are associated with poorer treatment response, yet pharmacological options for PTSD remain limited. Here, we review evidence that PTSD and metabolic disease share convergent mechanisms, including dysregulation of the hypothalamic–pituitary–adrenal axis, glucocorticoid receptor signaling, neuroinflammation, insulin resistance and mitochondrial dysfunction. We evaluat